Tables
- TABLE 1
Summary of the number needed to treat (NNT) with the influenza vaccine in different age groups to protect against influenza
NNT against influenza Relative risk (95% CI) Age 3–16 years (LAIV) 7 0.22 (0.11–0.41) Age 2–16 years (IIV) 5 0.36 (0.28–0.48) Healthy adults 71 0.41 (0.36–0.47) Age >65 years 30 0.42 (0.27–0.66) Data compiled from Cochrane reviews on influenza vaccination preventing influenza in healthy adults, children and >65-year-olds [33–35]. LAIV: live attenuated influenza vaccine; IIV: inactivated influenza vaccine.
- TABLE 2
Summary of the influenza vaccine recommendations made in the joint Department of Health and Social Care, Public Health England and NHS England “annual flu letter”
Vaccine Age 2–17 years Quadrivalent LAIV Age 18–64 years (in clinical high-risk group due to illness, plus pregnant women, those in residential homes, carers, close contacts of immunocompromised) Quadrivalent influenza vaccine: standard egg-grown or newly licensed cell-based vaccines Age ≥65 years Adjuvanted trivalent influenza vaccine or cell-based quadrivalent influenza vaccine. High-dose trivalent vaccine is licensed, but not currently funded under the NHS as it has a significantly higher price LAIV: live attenuated influenza vaccine; NHS: National Health Service.